Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805180 | 0.91 | REN (0.48) | RENCYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL2811094 | 0.88 | REN (0.55) | RENCYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL3072690 | 0.88 | REN (0.55) | RENCYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL8004572 | 0.86 | REN (0.42) | RENCYP2C9CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL89417 | 0.84 | REN (0.59) | RENCYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL15087927 | 0.83 | REN (0.56) | RENCYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL89400 | 0.83 | REN (0.62) | RENCYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL2807782 | 0.83 | REN (0.50) | RENCYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL2237924 | 0.83 | REN (0.54) | RENCYP2C9CYP1A2CYP2C19POLB | |
| SCHEMBL2241026 | 0.82 | ALDH1A1 (0.54) | RENCYP2C9CYP1A2CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| EP-2168952-A1 | MORPHOLINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009106599-A2 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885CYP2C9 257/4885CYP2D6 132/4885 |
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | REN 1/4885CYP2C9 63/4885CYP2D6 46/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | REN 1/4885CYP2C9 63/4885CYP2D6 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.